Amgen Inc ( AMGN - Free Report ), Gilead Sciences ( GILD - Free Report ), Biogen Inc ( BIIB - Free Report ) and Alexion Pharmaceuticals, all beat earnings and revenue estimates (read: Forget Big Tech, Biotech ETFs are Soaring Higher ). Earnings in Focus Amgen reported second-quarter 2017 adjusted earnings of $3.27 per share on July 25, 2017, beating the Zacks Consensus Estimate of $3.09 and increasing more than 15.1% from $2.84 per share in the year-ago quarter. Moreover, it also beat the consensus estimate on the revenue front. The company reported revenues of $5.810 billion, which surpassed the consensus estimate of $5.666 billion and increased 2.14% from $5.688 billion in the year-ago quarter. The company updated its full-year non-GAAP EPS guidance to the range of $12.15–$12.65 from $12–$12.6. It also updated its revenue guidance to the range of $22.5–$23 billion from $22.3–$23.1 billion.